– UK, Cambridge / USA, IN – Acacia Pharma Group Plc (EBR: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, today announced the appointment of Alessandro Della Chà to its Board as a non-executive Director.
This appointment is in accordance with the right of Cosmo Technologies Limited, a wholly-owned subsidiary of Cosmo Pharmaceuticals N.V., to appoint a director to the Board under the terms of the strategic in-licensing, investment and loan transaction entered into in January 2020.
Alessandro Della Chà has been a board member of Cosmo Pharmaceuticals N.V. since 2006 and has been its CEO since 27 March 2014.
“I am delighted to welcome Alex as a company director. His background and expertise will be a valuable addition to the board,” said Commenting, Scott Byrd, Board Chairman.
About Alessandro Della Chà
Until 27 March 2014, he was a senior partner at Studio Legale Edoardo Ricci e Associati, Milan, where he specialized in company law, mergers and acquisitions. He joined the firm in 1988. From 1987 to 1988 he was assistant of the central director for corporate matters at Fininvest Group. From 1994 to 1998 he was director of II.PP.A.B. Milan, a charitable institution owning hospitals and specialized in elderly care.
Alessandro Della Chà has a degree in law from the University of Milan, Italy, and an LL.M. in European Union commercial law from the University of Leicester, United Kingdom. He is a lecturer in conferences and seminars held by universities and institutions on commercial and company law issues.
About Acacia Pharma
Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy. The Company has identified important and commercially attractive unmet needs in these areas that its product pipeline aims to address.
Acacia Pharma’s lead product, BARHEMSYS is approved in the US for the treatment and prophylaxis of postoperative nausea & vomiting, with US launch planned for H2 2020.
BYFAVO, an ultra-short-acting and reversible sedative/anesthetic for use during invasive medical procedures, such as colonoscopy and bronchoscopy, is in-licensed from Cosmo Pharmaceuticals for the US market. The NDA for BYFAVO has been filed with the US FDA and the target PDUFA action date is now 5 July 2020.
APD403, a selective dopamine antagonist for chemotherapy-induced nausea & vomiting has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy.
Acacia Pharma is based in Cambridge, UK and its US operations are centred in Indianapolis, IN. The Company is listed on the Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker symbol ACPH.
For more information: http://acaciapharma.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
